Prognostic value of site-specific metastases in lung cancer: A population based study

Abstract

Background : Studies on prognosis of different metastasis sites in patients with lung cancer are limited. The aim of present study was to investigate the prognostic value of metastases sites among patients with metastatic lung cancer. Methods : Between 2010 and 2014, patients diagnosed with metastatic lung cancer were selected using the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier methods were adopted and multivariable Cox regression models were built to compare the prognosis of different metastasis sites. Results : A total of 54,697 eligible patients were identified, including 10,945 (20.0%) patients had isolated bone metastases, 8,294(15.2%) with isolated brain metastases, 5,677(10.4%) with isolated liver metastases, 9,430(17.2%) with isolate lung metastases, and 20,351(37.2%) with multiple organ metastases. The percentage of bone, brain, liver, lung and multisite metastases were 22.3%, 15.4%, 6.1%, 20.1% and 36.1% for non-small cell lung cancer (NSCLC), 12.5%, 14.3%, 24.3%, 7.9%, and 40.9% for small cell lung cancer (SCLC), the difference was statistical(P<0.001). In univariate and multivariable analysis, patients with liver metastases demonstrated a statistically significant disadvantage in cause-specific survival, while those with lung metastases have reduced risk of died of metastases when compared with brain metastases(P<0.001).The difference was consistent when make subgroup analysis in both NSCLC and SCLC(P<0.001). Conclusions : In patients with distant metastases, those with liver metastases have the poorest survival, whereas those with lung metastases have the best survival. Therefore, we should take into consideration of such discrepancy when making treatment strategies.

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer

“…Moreover, the proportion of patients with brain metastases (36%) and liver metastases (27%) were high in our study. SCLC patients with brain metastases and/or liver metastases have a worse prognosis, 26 although there were no statistical differences in PFS and OS between patients with and without brain metastases, or between patients with and without liver metastases in our study (Table 3). The median OS is 4 to 5 months for patients with recurrent or chemorefractory SCLC 27 .…”

Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data

“…Previous studies showed that the numbers of distant metastases were significantly correlated with outcomes in some types of cancer 25 , 26 , but a similar correlation was not seen in pancreatic cancer. Oweira et al found no significant difference in OS between pancreatic cancer patients with single metastasis and multiple metastases (P=0.409) 10 .…”

Ring finger protein 180 is associated with biological behavior and prognosis in patients with non‑small cell lung cancer

“…Despite the decline in the rate of non-small cell lung cancer (NSCLC) in recent years, it remains the leading cause of cancer mortality worldwide, 1.8 million people are diagnosed with lung cancer, and 1.6 million individuals died as a result of the disease in 2017 worldwide (1). Accurate diagnosis and precise prognostic predictions are critical for targeted treatment and prolonging the overall survival of patients with NSCLC (2). However, commonly used biomarkers, such as carcino-embryonic antigen and Cyfra21-1, offer low sensitivity and specificity and are not appropriate for clinical applications (3,4).…”